This report provides:
An overview of the global market for prescription generic drugs used in the
treatment of diabetes and devices and instruments used for diagnosis and
monitoring of diabetes, with a focus on Asia
Analyses of global market trends, with data from 2011, estimates for 2012, and
projections of compound annual growth rates (CAGRs) through 2017
Identification of markets based on epidemiological data and projections, plus
information on R&D trends and differential market potential on a
Discussion of healthcare policies, demographics, and the wider economic
Examination of therapeutic categories, such as insulins and oral hypoglycemic
agents, and devices including blood glucose monitors and accessories
Patent analysis Comprehensive company profiles of major players.
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology, and industry
analyses to help readers quantify and qualify the market for drugs used in the
treatment of diabetes and for devices and instruments used in the diagnosis
and monitoring of diabetes. Special emphasis is given to major forces
contributing to the vigorous growth of the diabetes market. Important trends
are identified and sales forecasts by product categories and major country
markets are provided through 2017. These forecasts are based on
epidemiological data and projections, as well as on information about R&D
trends and differential market potential on a country-by-country basis.
Health care policies, demographics, and the wider economic environment are
also taken into account.
REASONS FOR DOING THE STUDY
It is widely recognized that the prevalence of the most common type of
diabetes mellitus, Type 2, is now reaching epidemic proportions all over the
world. Cases of Type 1 diabetes are also on the rise, although to a less
spectacular degree. These trends are of great concern, not only to the
individuals affected, but also to governments and providers of health care.
Indeed, the economic consequences of diabetes are vast, involving not only the
direct burden of managing the disease but also the common and often
catastrophic complications such as cardiovascular disease, peripheral
neuropathy, and blindness.
Prompt diagnosis and effective treatment of diabetes are essential, not
optional, priorities for governments and health care agencies. The already
large market for diabetes monitoring and treatment will certainly grow in line
with increasing incidence and with improvements in diagnosis. Thus diabetes
is of great commercial significance to the suppliers of drugs used in
treatment and to the suppliers of devices needed for disease monitoring.
Among the information needs of companies in this field is an accurate and
up-to-date assessment of the current extent of the diabetes epidemic, its
likely evolution over the next five years, and the impact of drugs and
technical developments now in the pipeline.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends in the
context of the current size and growth of the diabetes market, discussed both
in global terms and in terms of the most important national markets.
Companies in the relevant pharmaceutical and medical industries are discussed,
with profiles of the leaders and an update on merger and acquisition (M&A)
activity. Five-year global sales forecasts are provided for main drug and
device categories, and breakdowns are provided for several national markets.
A comprehensive refresher course on diabetes is provided as an appendix.
MARKET ANALYSES AND FORECASTS
The dimensions of the surging diabetes epidemic can be witnessed in stark
outline against previous smaller estimates only a few years back. Increased
awareness of this "modern plague" has led naturally to improved and more
frequent testing practices. This new awareness has also led to improved
treatment compliance by patients. Added to these are the more expensive
therapies and increased penetration of continuous glucose monitoring (CGM)
approaches, which all combine to build a public health menace of accelerating
For the purpose of market analyses in this report, the global market is
defined as 13 countries which together make up over 80% of the total diabetes
universe. These countries are the U.S., Canada, Brazil, Mexico, China, India,
Japan, Russia, Germany, France, Italy, Spain and the U.K.
Market figures are based on revenues at the manufacturer level and are
projected at 2012-dollar value without attempting to predict the effect of
inflation/deflation. Therapeutic categories discussed include insulins and
oral hypoglycemic agents, devices including blood glucose monitors and
accessories, and software aids to self-management of diabetes by patients.
Primary research for this report included interviews with leading individuals
in relevant companies and medical associations; primary sources of published
data include epidemiological and economic studies, company annual reports, SEC
filings, and government publications. Secondary sources consisted of
literature searches, industry journals, and other commercial publications.
Data for market estimates and forecasts were pooled from a range of sources,
critically assessed by BCC.
This report is designed to satisfy the information needs of a wide variety of
individuals involved in the diabetes marketplace, including company senior
management executives seeking to base their strategic decisions on the best
available information with regard to market forces and trends. However, it is
also aimed at managers and executives in marketing, research, planning, and
sales departments who need readable, comprehensive, and up-to-date background
information on the marketplace in which they are operating.
Sources of information included marketing strategists, industry executives,
government and professional agencies, and surveys of physicians. Company
annual reports and SEC filings, journal articles, and data from health care
institutions were also mined, as well as publications of relevant associations
such as the International Diabetes Federation and the American and British
Paul Evers has been involved in analyzing pharmaceutical and medical markets
for 20 years. He is the author of previous reports on the diabetes
marketplace covering both therapeutic and monitoring aspects.